Reuters: A narrowly divided U.S. Food and Drug Administration panel of outside experts on Thursday voted to modify market restrictions on GlaxoSmithKline's diabetes drug Avandia, the one-time blockbuster at the center of one of the biggest drug controversies in recent years.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now